China Universal Asset Management Co. Ltd. Acquires 2,410 Shares of argenx SE (NASDAQ:ARGX)

China Universal Asset Management Co. Ltd. increased its position in argenx SE (NASDAQ:ARGX - Free Report) by 64.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,174 shares of the company's stock after buying an additional 2,410 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in argenx were worth $3,347,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ARGX. Price T Rowe Associates Inc. MD grew its position in shares of argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company's stock valued at $2,167,235,000 after purchasing an additional 1,830,651 shares during the period. Janus Henderson Group PLC raised its holdings in argenx by 24.8% in the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company's stock valued at $872,690,000 after buying an additional 439,889 shares during the period. Clearbridge Investments LLC raised its stake in shares of argenx by 36.5% in the 1st quarter. Clearbridge Investments LLC now owns 596,277 shares of the company's stock valued at $234,766,000 after acquiring an additional 159,480 shares during the period. Perpetual Ltd acquired a new position in shares of argenx during the third quarter worth about $76,314,000. Finally, Logos Global Management LP purchased a new stake in shares of argenx during the second quarter valued at approximately $58,055,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenx Stock Down 0.3 %

ARGX stock traded down $1.59 during trading hours on Tuesday, hitting $552.88. The company's stock had a trading volume of 220,613 shares, compared to its average volume of 306,427. The company has a market capitalization of $32.86 billion, a PE ratio of -97.96 and a beta of 0.63. The stock has a 50 day moving average price of $535.45 and a two-hundred day moving average price of $461.59. argenx SE has a 12 month low of $327.73 and a 12 month high of $571.97.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Barclays upgraded shares of argenx from an "equal weight" rating to an "overweight" rating in a research note on Tuesday, August 6th. Guggenheim reaffirmed a "buy" rating and set a $585.00 target price on shares of argenx in a report on Thursday, September 26th. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a "buy" rating to a "hold" rating in a research note on Friday, October 4th. Wedbush raised their price target on argenx from $519.00 to $560.00 and gave the stock an "outperform" rating in a report on Friday, July 26th. Finally, Truist Financial lifted their price objective on shares of argenx from $480.00 to $540.00 and gave the company a "buy" rating in a research report on Monday, July 22nd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $550.44.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.